BRAF Mutations in Thyroid Cancer

Clinical Pearls

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discussesBRAFmutations in thyroid cancer.

• The BRAF pathway is a good target, though predictive nature depends largely on the agent
• Both the BRAF and MAPK pathways are extremely dynamic
• MAPK is an important pathway, regardless of upregulation of the BRAF wild type pathway